Synphatec raises over USD 50 million in Series A, advised by CEC Capital Group

• Synphatec closed an over USD 50 million Series A private financing, with CEC Capital as sole financial adviser.
• Decheng Capital led the round; Huatai Genscript Fund, China Merchants Venture joined; existing investors including Morningside Ventures added capital.
• Shanghai-based Synphatec, founded in 2021, develops next-generation therapies for central nervous system disorders such as depression, Alzheimer’s disease.
• Proceeds to advance SP-101 and SP-201 into clinical development, with both core programs nearing proof-of-concept studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEC Capital Group published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.